Definitive chemoradiation for the treatment of locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4146-4152

  Blackstock, A William ^a   Govindan, Ramaswamy ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; LOMUSTINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG SAFETY; ESOPHAGITIS; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; LUNG TUMOR; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS;

EID: 34748848082     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.6581     Document Type: Review

References (41)

1. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
2. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
3. Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
4. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
5. Le Chevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84:58, 1992
6. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer: A randomized, phase III trial. Ann Intern Med 115:681-686, 1991
7. Ihde DC: Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Intern Med 115:737-739, 1991
8. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis. Cancer 76:593-601, 1995
9. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
10. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
11. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
12. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
13. Fournel P, Robinet G, Thomas P, et al: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910-5917, 2005
14. Huber RM, Flentje M, Schmidt M, et al: Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24:4397-4404, 2006
15. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46:87-98, 2004
16. Curran WJ Jr, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential v. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
17. Albain KS, Crowley JJ, Turrisi AT 3rd, et al: Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460, 2002
18. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
19. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005
20. Komaki R, Scott C, Ettinger D, et al: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149-155, 1997
21. Clamon G, Herndon J, Cooper R, et al: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11, 1999
22. Gervais R, Ducolone A, Le Chevalier T, et al: Conventional radiation (RT) with daily carboplatin (Cb) compared to RT along after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatin (P)]: Final results of a randomized phase III trial in stage III unresectable non small cell lung cancer (NSCLC) - Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 23:625s, 2005 (suppl; abstr 7016)
23. Vokes EE, Herndon JE II, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 20:4191-4198, 2002
24. Vokes EE, Herndon JE II, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007
25. Bedano PM, Neubauer M, Ansari R, et al: Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. J Clin Oncol 24:374s, 2006 (suppl; abstr 7043)
26. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
27. Seiwert TY, Connell PP, Mauer AM, et al: A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. J Clin Oncol 23:635s, 2005 (suppl; abstr 7062)
28. Bogart JA, Govindan R: A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin Lung Cancer 7:285-287, 2006
29. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
30. Kelly K, Chansky K, Gaspar LE, et al: Updated analysis of SWOG 0023: A randomized phase III trial of gefitnib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 25:388s, 2007 (abstr 7513)
31. Rischin D, Burmeister B, Mitchell P, et al: Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. J Clin Oncol 22:635s, 2004 (abstr 7077)
32. Ready N, Janne P, Herndon J, et al: Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. J Clin Oncol 24:375s, 2006 (abstr 7046)
33. Werner-Wasik M, Swan S, Curran W, et al: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 trial. J Clin Oncol 23:654s, 7135, 2005 (suppl 16S; abstr 7135)
34. Hoffman PC, Mauer AM, Haraf DC, et al: A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23:648s, 2005 (suppl 16S; abstr 7113)
35. Food and Drug Administration: Important drug warning regarding Avastin (bevacizumab). www.fda.gov/medwatch/safety/2007/ Avastin_DHCP_TEF_Final_April2007.pdf
36. Perez CA, Bauer M, Edelstein S, et al: Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539-547, 1986
37. Bradley JD, Graham M, Suzanne S, et al: Phase I results of RTOG L-0117: A phase I/II dose intensification study using 3dCRT and concurrent chemotherapy for patients with inoperable NSCLC. J Clin Oncol 23:636s, 2005 (suppl 16S; abstr 7063)
38. Schild S: Results of a phase I/II trial of concurrent chemotherapy and escalating doses of radiation for unresectable non small cell lung cancer. Int J Radiat Oncol Biol Phys 63:S44, 2005 (suppl)
39. Socinski MA, Rosenman JG, Halle J, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified phase I/II trial. Cancer 92:1213-1223, 2001
40. Blackstock AW, Ho C, Butler J, et al: Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 1:434-440, 2006
41. Blackstock AW, Socinski MA, Bogart J, et al: Induction plus concurrent chemotherapy with high dose (74 Gy) 3-dimensional thoracic radiotherapy in stage III non small cell lung cancer (NSCLC): Preliminary report of the Cancer and Leukemia Group B (CALGB) 30105. J Clin Oncol 24:374s, 2006 (suppl; abstr 7042)